Dynavax Technologies Corporation (DVAX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol DVAX
- Company Dynavax Technologies Corporation
- Price $15.38
- Changes Percentage 0
- Change 0
- Day Low $15.37
- Day High $15.41
- Year High $15.49
- Year Low $9.2
- Market Cap $1,805,944,223
- Price Avg 50 EMA (D) $10.95
- Price Avg 200 EMA (D) $10.78
- Exchange NASDAQ
- Volume 6,094,960
- Average Volume 2,136,225
- Open $15.39
- Previous Close $15.38
- EPS -0.37
- PE -41.57
- Earnings Announcement 2026-02-19 12:00:00
- Shares Outstanding $117,421,601
Company brief: DYNAVAX TECHNOLOGIES CORPORATION (DVAX )
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Mr. Ryan Spencer
- https://www.dynavax.com
- US
- N/A
- 02-19-2004
- US2681582019
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
DVAX Corporation News
Why Dynavax Stock Soared Today
fool.com -- Sanofi is launching an all-cash tender offer for Dynavax's shares. The French pharma giant's bid comes at a sizable premium to Dynavax's recent closing price....
Dynavax Technologies Stock Soars on Buyout Buzz
schaeffersresearch.com -- Biotech stock Dynavax Technologies Corp (NASDAQ:DVAX) is soaring today, last seen up 38.7% at $15.43, after reports that Sanofi (SNY) plans to acquire the company in an all-cash deal worth roughly $2...
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
prnewswire.com -- MILWAUKEE , Dec. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Dynavax (Nasdaq: DVAX) for possible breaches of fiduciary duty and other violations of law in its recently announced transacti...
Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying
investopedia.com -- Shares of Dynavax Technologies (DVAX) skyrocketed after French drugmaker Sanofi (SNY) said it would buy the biopharmaceutical firm for $2.2 billion to expand its Hepatitis B offerings and enter the sh...
Biggest Mover Wednesday: Dynavax Stock Soars on $2.2 billion Acquisition Deal
gurufocus.com -- Shares of Dynavax Technologies (DVAX) surged about 37% on early Wednesday after French drugmaker Sanofi (SNY) agreed to buy the U.S. vaccine company in a cash d...
DVAX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Dynavax Technologies Corporation is Fair to Shareholders
businesswire.com -- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Dynavax Technologies Corporation (NASDAQ: DVAX) to Sanofi for $15.50 per share in cash is...